Research Analysts’ Weekly Ratings Updates for Teleflex (TFX)

Several analysts have recently updated their ratings and price targets for Teleflex (NYSE: TFX):

• 4/14/2026 – Teleflex had its “sector perform” rating reaffirmed by Royal Bank Of Canada.
• 4/13/2026 – Teleflex was upgraded by Bank of America Corporation from “underperform” to “neutral”. They now have a $135.00 price target on the stock.
• 3/27/2026 – Teleflex had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 3/27/2026 – Teleflex was upgraded by Raymond James Financial, Inc. from “market perform” to “outperform”. They now have a $128.00 price target on the stock.
• 3/7/2026 – Teleflex was downgraded by Wall Street Zen from “hold” to “sell”.
• 3/2/2026 – Teleflex was downgraded by Zacks Research from “hold” to “strong sell”.
• 2/27/2026 – Teleflex had its price target raised by Royal Bank Of Canada from $115.00 to $125.00. They now have a “sector perform” rating on the stock.
• 2/27/2026 – Teleflex had its price target raised by Wells Fargo & Company from $116.00 to $130.00. They now have an “equal weight” rating on the stock.
• 2/26/2026 – Teleflex had its price target raised by Needham & Company LLC from $138.00 to $147.00. They now have a “buy” rating on the stock.

Teleflex Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 31st. Investors of record on Friday, March 6th were paid a $0.34 dividend. The ex-dividend date was Friday, March 6th. This represents a $1.36 dividend on an annualized basis and a yield of 1.1%. Teleflex’s dividend payout ratio (DPR) is -6.62%.

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.